Katalyst Securities LLC v. Marker Therapeutics, Inc.

CourtDistrict Court, S.D. New York
DecidedMarch 9, 2022
Docket1:21-cv-08005
StatusUnknown

This text of Katalyst Securities LLC v. Marker Therapeutics, Inc. (Katalyst Securities LLC v. Marker Therapeutics, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Katalyst Securities LLC v. Marker Therapeutics, Inc., (S.D.N.Y. 2022).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK KATALYST SECURITIES, LLC, Petitioner, 21-CV-08005-LTS -against- MARKER THERAPEUTICS, INC., Respondent

MEMORANDUM ORDER

In this removed action, petitioner Katalyst Securities, LLC (“Katalyst”, or the “Petitioner”) seeks confirmation of an arbitration award (the “Award”) rendered by a panel of Financial Industry Regulatory Authority (“FINRA”) arbitrators (the “Panel”) against respondent Marker Therapeutics (“Marker”, or the “Respondent”), on August 16, 2021, as well as pre- judgment and post-judgment interest and costs (docket entry no. 1, Ex. A (the “Petition”) at 4-5.) Marker’s motion to vacate the award (docket entry no. 12, “Resp. Mem.”) is now before the Court. Marker argues that the panel of arbitrators lacked jurisdiction to arbitrate the dispute between the two parties and, in the alternative, that the FINRA panel’s award demonstrated a manifest disregard of the applicable law. (Resp. Mem.) Katalyst opposes the motion and requests the entry of judgment granting its petition. The Court has jurisdiction of this action pursuant to 28 U.S.C. section 1332 and 28 U.S.C. section 1441. The Court has reviewed the parties’ submissions thoroughly and, for the following reasons, Katalyst’s Petition to confirm the Award is granted. Marker’s motion to vacate the Award is denied. BACKGROUND This dispute arises from a contract (Docket entry no. 13, Ex. 2 (the “Agreement”)) entered into between Petitioner Katalyst, a registered broker-dealer and FINRA member (Agreement at 1) and Marker, a publicly traded immune-oncology company1 (together, the

“Parties”). (Id.) Under the terms of the Agreement, Marker appointed Katalyst “to assist the Company in finding qualified subscribers” for the private placement of Marker’s securities in exchange for a fee to be paid in cash and in warrants to purchase shares in Marker’s stock. (Agreement at 1 & ¶ 3(a-b).) The Agreement also contained a clause providing that Katalyst would be entitled to an additional fee should any investor “introduced” by Katalyst to Marker “consummate” financing for Marker during a one-year “tail period” following the 2017 private placement. (Agreement ¶ 3(c).) The Agreement contained a two-stage dispute resolution mechanism. In the event of a dispute, the Parties agreed to first “submit the matter for resolution to a mediator, acceptable to all parties.” (Agreement ¶ 13.) If mediation failed, the parties agreed that “the matter will be

resolved by arbitration.” (Id.) As to arbitration, the Agreement provided as follows: The parties hereto agree to submit all controversies to the exclusive jurisdiction of FINRA arbitration in accordance with the provisions set forth below and understand that . . . arbitration is final and binding on all parties . . . and all controversies which may arise between the parties concerning this agreement shall be determined by arbitration pursuant to the rules then pertaining to FINRA.

(Agreement ¶ 13, the “Arbitration Clause”.) The Arbitration Clause also included a choice of law provision, stating that “[a]ll questions concerning the construction, validity,

1 The parties to the Agreement are Katalyst and TapImmune Inc., Marker’s predecessor-in- interest. (Docket entry no. 12 (“Resp. Mem.”) at 3 n. 1.) For purposes of clarity, and consonant with the usage of the Parties, the Court will refer to the Respondent only as Marker. enforcement, and interpretation of this agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York.” (Id.) A controversy subsequently arose when Katalyst claimed that Marker had obtained financing during the “tail period” from investors that Katalyst had “introduced,” as

defined by the Agreement, to Marker. (Resp. Mem. at 2.) Marker denied any contractual obligation to compensate Katalyst in connection with that later financing, and the matter was referred to mediation as required under the Agreement’s terms. (Docket entry no. 15 (the “Oppenheimer Decl.”), Ex. 3 at 16.) Mediation failed to resolve the dispute, and on May 20, 2019, Katalyst submitted a Statement of Claim to FINRA for arbitration. (Oppenheimer Decl., Ex. 2.) During the arbitration process, Marker “repeatedly objected” to FINRA’s assertion of jurisdiction over the dispute, despite the terms of the Arbitration Clause. (Resp. Mem. at 5.) Each time, Marker’s objection was overruled. (See docket entry no. 13 (the “Kuwana Decl.”), at Ex. 4.) (Containing an e-mail from the Panel to the Parties, stating “The Panel has determined that FINRA has jurisdiction over this matter pursuant to the terms of the parties’ agreement.”)

On August 16, 2021, FINRA issued a decision, awarding Katalyst $1,798,501.00 in compensatory damages, $450,000.00 in attorney’s fees, and pre-award interest. (Kuwana Decl., Ex. 3. (the “Award”). Katalyst subsequently filed the Petition in the Supreme Court of New York, New York County, seeking confirmation of the Award, and Marker removed the action to this Court. DISCUSSION

Jurisdiction “Arbitration is a matter of contract between the parties; it is a way to resolve disputes – but only those disputes – that the parties have agreed to submit to arbitration.” DDK Hotels, LLC v. Williams-Sonoma, Inc., 6 F.4th 308, 316 (2d Cir. 2021) (quotation and citation omitted). “Just as the parties may elect through their contract to have arbitrators (rather than a court) resolve categories of disputes between them, they may similarly contract to have arbitrators (rather than a court) decide whether a particular dispute is to be arbitrated under the terms of the contract.” Metro Life Ins. Co. v. Bucsek, 919 F.3d 184, 189-90 (2d Cir. 2019).

“[T]he question of who decides arbitrability is itself a question of contract.” Henry Schein, Inc. v. Archer and White Sales, Inc., 139 S. Ct. 524, 527 (2019). “When the parties’ contract delegates the arbitrability question to an arbitrator, the courts must respect the parties’ decision as embodied in the contract.” Id. at 528. “In determining whether the arbitrability of a dispute is to be resolved by the court or the arbitrator, the arbitration agreement is determinative.” DDK Hotels, 6 F.4th at 318 (citing First Options of Chicago, Inc. v. Kaplan, 115 S. Ct. 1920 (1995)). In reviewing an arbitration agreement, “[c]ourts should not assume that parties agreed to arbitrate arbitrability unless there is clear and unmistakable evidence that they did so.” First Options, 115 S. Ct. at 1924 (internal quotation omitted). “Rarely, however, do arbitration

agreements directly state whether the arbitrator or the court will decide the issue of arbitrability.” DDK Hotels, 6 F.4th at 318 (internal modifications and quotation omitted). “In the absence of such clear language, ‘courts must look to other provisions of the agreements to see what contractual intention can be discerned from them.’” Id. (quoting Bucsek, 919 F.3d at 191.) If the parties “clearly and unmistakably agreed to have” the issue of arbitration resolved by the arbitrator, “it is the obligation of the court to enforce their agreement.” Bucsek, 919 F.3d at 191. Courts in the Second Circuit have repeatedly “found the clear and unmistakable provision [standard] satisfied where a broad arbitration clause expressly commits all disputes to

arbitration, concluding that all disputes necessarily includes disputes as to arbitrability,” NASDAQ OMX Group, Inc. v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

First Options of Chicago, Inc. v. Kaplan
514 U.S. 938 (Supreme Court, 1995)
Cappiello v. ICD Publications, Inc.
720 F.3d 109 (Second Circuit, 2013)
T. CO METALS, LLC v. Dempsey Pipe & Supply, Inc.
592 F.3d 329 (Second Circuit, 2010)
Smith Barney Shearson Inc. v. Sacharow
689 N.E.2d 884 (New York Court of Appeals, 1997)
NASDAQ OMX Group, Inc. v. UBS Securities, LLC
770 F.3d 1010 (Second Circuit, 2014)
Henry Schein, Inc. v. Archer & White Sales, Inc.
586 U.S. 63 (Supreme Court, 2019)
DDK Hotels, LLC v. Williams-Sonoma, Inc.
6 F.4th 308 (Second Circuit, 2021)
Beijing Shougang Mining v. Mongolia
11 F.4th 144 (Second Circuit, 2021)
Metro. Life Ins. Co. v. Bucsek
919 F.3d 184 (Second Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Katalyst Securities LLC v. Marker Therapeutics, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/katalyst-securities-llc-v-marker-therapeutics-inc-nysd-2022.